Loading stock data…
Biogen Inc. (BIIB)
$212.50-8.33 (-3.77%)
Market ClosedLast close Sep 8
Biogen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biogen Inc. in the Healthcare sector is trading at $212.50 with a market capitalization of $30.6B. Wall Street consensus targets $236.87 (31 analysts), implying a +11.5% move over the next 12 months. The stock is currently near its 52-week high of $225.80, remaining 11.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.74B↑ | $2.48B↑ | $2.28B↓ | $2.53B↓ | $2.65B |
| Gross Profit | $1.96B↑ | $1.82B↑ | $1.78B↓ | $1.86B↓ | $2.04B |
| Operating Income | $482.80M↑ | $459.80M↑ | $385.50M↓ | $606.50M↓ | $851.80M |
| Net Income | $97.50M↓ | $319.50M↑ | -$48.90M↓ | $466.50M↓ | $634.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.92
Beta
Defensive asset. Lower volatility than the S&P 500.
0.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.43%
Volume
Today's trading volume
617,405
Recent News
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...